BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 4722913)

  • 1. Development of four-drug BCNU combination chemotherapy regimens.
    Durant JR; Lessner HE
    Cancer; 1973 Aug; 32(2):277-85. PubMed ID: 4722913
    [No Abstract]   [Full Text] [Related]  

  • 2. Primary treatment of disseminated Hodgkin's disease with BCNU alone and in combination with vincristine, procarbazine, and prednisone.
    Harrison DT; Neiman PE
    Cancer Treat Rep; 1977 Aug; 61(5):789-95. PubMed ID: 329978
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemotherapy of Hodgkin's disease in studies by acute leukemia group B.
    Nissen NI; Stutzman L; Holland JF; Glidewell OJ
    Arch Intern Med; 1973 Mar; 131(3):396-401. PubMed ID: 4688038
    [No Abstract]   [Full Text] [Related]  

  • 4. Updated Hodgkins' disease. C. Advanced disease and special problems. Advances in chemotherapy.
    Frei E; Luce JK
    JAMA; 1973 Jan; 223(2):166-8. PubMed ID: 4739456
    [No Abstract]   [Full Text] [Related]  

  • 5. Eastern cooperative oncology group studies.
    Lenhard RE
    Arch Intern Med; 1973 Mar; 131(3):418-20. PubMed ID: 4688039
    [No Abstract]   [Full Text] [Related]  

  • 6. [On the therapy of lymphogranuloma. CCNU (1(2-chlorethyl)-3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4].
    Brunner KW; Maurice P; Sonntag RW
    Schweiz Med Wochenschr; 1972 Oct; 102(43):1546-51. PubMed ID: 4647016
    [No Abstract]   [Full Text] [Related]  

  • 7. 1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma.
    Durant JR; Loeb V; Dorfman R; Chan YK
    Cancer; 1975 Dec; 36(6):1936-44. PubMed ID: 1106833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy of advanced Hodgkin's disease. A review.
    Goldsmith MA; Carter SK
    Cancer; 1974 Jan; 33(1):1-8. PubMed ID: 4129559
    [No Abstract]   [Full Text] [Related]  

  • 9. [Progress in combination chemotherapy of malignant lymphomas (author's transl)].
    Senn HJ
    Schweiz Rundsch Med Prax; 1973 Dec; 62(51):1589-94. PubMed ID: 4771027
    [No Abstract]   [Full Text] [Related]  

  • 10. Southeastern Cancer Study Group trials with nitrosoureas in Hodgkin's disease.
    Durant JR; Bartolucci A; Gams RA; Dorfman RF; Velez-Garcia E
    Cancer Treat Rep; 1976 Jun; 60(6):781-7. PubMed ID: 782700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current chemotherapeutic combinations.
    DeVita VT; Carbone PP
    Ser Haematol; 1973; 6(2):182-95. PubMed ID: 4593779
    [No Abstract]   [Full Text] [Related]  

  • 12. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
    Bakemeier RF; Anderson JR; Costello W; Rosner G; Horton J; Glick JH; Hines JD; Berard CW; DeVita VT
    Ann Intern Med; 1984 Oct; 101(4):447-56. PubMed ID: 6089632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination therapy in Hodgkin's disease consisting of vincaleukoblastine, cyclophosphamide and natulan].
    Zelechowska JA; Madej C; Leszczyk CZ; Dabrowska W; Pieńkowska F
    Nowotwory; 1975; 25(2):157-66. PubMed ID: 1144074
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cytostatic chemotherapy in lymphogranulomatosis].
    Stacher A
    Med Klin; 1973 Jul; 68(30):985-8. PubMed ID: 4131695
    [No Abstract]   [Full Text] [Related]  

  • 15. Single-agent therapy for Hodgkin's disease.
    Carter SK; Livingston RB
    Arch Intern Med; 1973 Mar; 131(3):377-87. PubMed ID: 4631683
    [No Abstract]   [Full Text] [Related]  

  • 16. Combined drug treatment of Hodgkin's disease: remission induction, remission duration, and survival; an appraisal.
    DeVita VT
    Natl Cancer Inst Monogr; 1973 May; 36():373-9. PubMed ID: 4744596
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical trials with BCNU (NSC-409962) in malignant lymphomas by the Eastern Cooperative Oncology Group.
    Bennett JM; Bakemeier RF; Carbone PP; Ezdinli E; Lenhard RE
    Cancer Treat Rep; 1976 Jun; 60(6):739-45. PubMed ID: 60176
    [No Abstract]   [Full Text] [Related]  

  • 18. [Response and survival after sequential monochemotherapy in malignant lymphocytic and histocytic lymphoma].
    Monfardini S; Tancini G; Gasparini M; Pizzetti F; De Lena M; Bonadonna G
    Tumori; 1973; 59(3):219-38. PubMed ID: 4580942
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination chemotherapy with vincristine, carmustine, carmustine (BCNU), and bleomycin in patients with squamous cell bronchial carcinoma resistant to cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP).
    Veronesi A; Magri MD; Trovò MG; Tirelli U; Galligioni E; Tumolo S; Grigoletto E
    Cancer Treat Rep; 1982 Oct; 66(10):1877-8. PubMed ID: 6181871
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemotherapy of the lymphomas.
    McElwain TJ
    Semin Hematol; 1974 Jan; 11(1):59-72. PubMed ID: 4859700
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.